Found 32 clinical trials
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.
- 80 views
- 10 Jul, 2018
- 53 locations
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
The purpose of this study is to determine whether Sodium Oxybate is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.
- 217 views
- 22 Feb, 2019
- 1 location
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN G3031 Compared to Placebo in Patients with Narcolepsy with and without Cataplexy
This is a study to evaluate how safe and effective an investigational medication (SUVN-G3031) is compared to placebo at reducing the excessive daytime sleepiness in patients with narcolepsy with
- 184 views
- 27 Jan, 2020
- 1 location
Sodium Oxybate in Idiopathic Hypersomnia
this study evaluates of the efficacy of sodium oxybate on excessive daytime sleepiness using Epworth sleepiness scale over 8 weeks compared to placebo
- 45 views
- 19 Feb, 2021
- 1 location
A Wearable Morning Light Treatment for Postpartum Depression
depression symptoms, excessive daytime sleepiness, maternal-infant bonding, social functioning, and sleep-related impairment from pre- to post-treatment.
- 2 views
- 07 Jul, 2021
- 1 location
TElemedicine for NARcolepsy
, metabolic, and psychosocial assessment. Primary (i.e., excessive daytime sleepiness according to the Epworth Sleepiness Scale) and secondary endpoints (i.e., other symptoms, metabolic control, quality of
- 0 views
- 26 Jan, 2021
- 1 location
Validation of Sleep Healthcare System
excessive daytime sleepiness (EDS) or polysomnographic parameters were identified. Among those metabolites, L-Kynurenine and g-Glutamylleucine were metabolites associated with EDS which generated the AUROC
- 0 views
- 23 Jan, 2021
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy
- 0 views
- 30 Aug, 2021
- 7 locations
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with
- 0 views
- 15 Sep, 2021
- 14 locations
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome Followed by an Open Label Extension
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi
- 0 views
- 09 Sep, 2021
- 13 locations